LeMaitre Vascular (NASDAQ:LMAT) Stock Passes Above 200-Day Moving Average – What’s Next?

LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $89.71 and traded as high as $108.68. LeMaitre Vascular shares last traded at $107.86, with a volume of 253,850 shares traded.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LMAT. Citizens Jmp lifted their target price on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Wells Fargo & Company lifted their price objective on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Finally, Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $105.80.

LeMaitre Vascular Stock Performance

The stock has a market cap of $2.46 billion, a price-to-earnings ratio of 42.97, a P/E/G ratio of 3.06 and a beta of 0.66. The firm’s 50-day moving average is $95.05 and its two-hundred day moving average is $89.71. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. During the same period in the previous year, the firm posted $0.49 EPS. LeMaitre Vascular’s revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be paid a $0.25 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio is presently 39.84%.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 55,930 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total value of $6,029,813.30. Following the transaction, the chief executive officer owned 1,476,500 shares in the company, valued at approximately $159,181,465. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David B. Roberts sold 8,464 shares of LeMaitre Vascular stock in a transaction on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 215,438 shares of company stock worth $23,062,911. 9.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently modified their holdings of the business. Advisors Asset Management Inc. boosted its position in LeMaitre Vascular by 3.0% during the second quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock worth $341,000 after acquiring an additional 118 shares during the last quarter. Illinois Municipal Retirement Fund raised its holdings in LeMaitre Vascular by 1.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after acquiring an additional 123 shares during the last quarter. NewEdge Advisors LLC lifted its stake in LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after purchasing an additional 139 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in LeMaitre Vascular by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock worth $971,000 after purchasing an additional 147 shares in the last quarter. Finally, Johnson Investment Counsel Inc. boosted its holdings in shares of LeMaitre Vascular by 0.5% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock worth $2,607,000 after purchasing an additional 153 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.